A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context
Authors:
- P BallPBP Ball
- L MandellLML Mandell
- G PatouGPG Patou
- W DanknerWDW Dankner
- G TillotsonGTG Tillotson
- 1 May 2004
- journal article
- review article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 23 (5) , 421-429
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Cardiotoxicity of fluoroquinolonesJournal of Antimicrobial Chemotherapy, 2002
- Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and MoxifloxacinPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?International Journal of Antimicrobial Agents, 2000
- Quinolone-induced QT interval prolongation: a not-so-unexpected class effectJournal of Antimicrobial Chemotherapy, 2000
- Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelinesDiagnostic Microbiology and Infectious Disease, 1999
- Fluoroquinolone Toxicity Profiles: A Review Focusing on Newer AgentsClinical Infectious Diseases, 1999
- Comparative Tolerability of the Newer Fluoroquinolone AntibacterialsDrug Safety, 1999
- Tolerability of Fluoroquinolone Antibiotics Past, Present and FutureDrug Safety, 1995
- Temafloxacin Syndrome: Review of 95 CasesClinical Infectious Diseases, 1994
- Structure-activity and structure-side-effect relationships for the quinolone antibacterialsJournal of Antimicrobial Chemotherapy, 1994